IceCure ProSense kidney cancer trial shows 89.4% recurrence-free rate at 4 years

• IceCure Medical on May 19, 2026 flagged clinical results that were already presented at ECIO 2026, highlighting its ProSense cryoablation system as a potential alternative to surgery in select solid tumors.
• In kidney cancer, a multicenter ICESECRET trial readout indicated most patients stayed free of recurrence over several years of follow-up, supporting broader use in small renal tumors.
• Separate early-stage breast cancer data from an independent cohort found no residual cancer on follow-up imaging, with patients reporting strong cosmetic satisfaction and low post-procedure burden.
• Additional independent fibroadenoma findings showed meaningful lesion shrinkage over a year, reinforcing a minimally invasive positioning that could expand addressable demand in breast indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605190830PR_NEWS_USPR_____IO62749) on May 19, 2026, and is solely responsible for the information contained therein.